Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On
July 26, 2022, the Company entered into an employment agreement (the “Employment Agreement”) with Eoin
Elliffe (the “Executive”) and appointed him as its Chief Risk Officer (“CRO”).
The following is a summary
of the material features of the Employment Agreement and is qualified in its entirety by reference to the full text of it, a copy of which
is filed as Exhibit 10.1 to this Report.
Base
Salary. The Executive’s initial annual base salary is $265,000 (“Base Salary”) subject to a
discussion of renegotiation each year by the Company and the Executive; however, the Company has no obligation to agree to an increase
in the Base Salary. The Base Salary may not be reduced absent changed economic circumstances of the Company (for example, where base salaries
are reduced across-the-board for members of senior management of the Company).
Bonus. The
Executive will be eligible for an annual bonus of 0-100% of his current Base Salary, which will be determined based upon achievement of
performance goals set by the Chief Executive Officer (“CEO”) of the Company annually at or near the beginning of each
calendar year; with an annual target bonus of 50% of the Base Salary (the “Target Bonus”). For the 2022 performance
year, the Executive will be paid a minimum annual bonus of $125,000. The Company, in the discretion of the CEO, may direct the Company
to pay a pro-rata Target Bonus if the Executive is not employed at the end of a calendar year; if his employment ceases due to death or
disability, a pro-rata Target Bonus must be paid.
Equity
Compensation. In connection with his employment the Executive was granted stock options to purchase 20,000 shares of
the Company’s voting common stock with an exercise price of $11.86, which was the fair market value as of July 27, 2022 (the
“Date of Grant”). The options vest in equal installments on the second and fourth anniversaries of the effective date
of the Date of Grant subject to the Executive’s continuous employment with the Company, and these options expire ten (10) years
from the Date of Grant.
Benefits. The
Company will provide the Executive retirement and such other benefits as are customarily provided to similarly situated executives of
the Company, including paid vacation, coverage under the Company’s medical, life, disability and other insurance plans, and reimbursement
for all reasonable business expenses in accordance with the Company’s expense reimbursement policy.
Termination.
Either the Company or the Executive may terminate the Agreement prior to the expiration of its initial term (from July 26, 2022 to
July 26, 2024) at any time upon written notice. The initial term automatically extends for additional one-year periods unless either
party gives notice not to renew at least ninety (90) days prior to the end of the initial or any renewal term.
Non-Competition.
During his employment with the Company and for a period indicated thereafter shown below, the Executive may not directly or indirectly
compete with the Company in any state, country or region in which the Company conducts business during the term of the Employee’s
employment (the “Non-Competition Period”).
Employment Term |
|
Non-Competition Period |
|
|
|
At least three (3) months |
|
Three (3) months |
At least six (6) months |
|
Six (6) months |
At least nine (9) months |
|
Nine (9) months |
Twelve (12) months or more |
|
Twelve (12) months |
Effect
of Termination; Severance.
In
the event of voluntary resignation of employment by the Executive without Good Reason (as defined
below), the Executive shall be entitled to payment of his Base Salary for the applicable Non-Competition
Period following his resignation as well as any earned but unpaid Target Bonus for the prior year; provided, that the Executive
is in compliance with the non-competition provisions of the Employment Agreement (the “Non-Competition Provisions”).
In
the event of a termination of employment due to (i) death, (ii) permanent disability or (iii) by the Company for Good Cause
(as defined below), the Executive will be entitled to payment of any earned but unpaid Base Salary,
Target Bonus and other benefits and unreimbursed business expenses.
In addition to the foregoing,
if (i) the Company terminates the Executive’s employment except for death, permanent disability or for Good Cause, (ii) the
Company elects not to renew this Agreement for an additional one-year term as set forth above or (ii) the Executive terminates his
employment for Good Reason (as defined below, and collectively a “Qualifying Termination”), the Executive
will be entitled to payment of any earned but unpaid Base Salary, Target Bonus and other benefits and unreimbursed business expenses,
as well as:
| (a) | Other than in connection with a Change of Control (as defined below) and provided that the Executive executes
and does not revoke the release attached as an exhibit to the Employment Agreement (the “Release”) and remains in compliance
with the Non-Competition Provisions, the Company will (i) pay the Executive, on a semi-monthly basis, his Base Salary and pro rata
Target Bonus for the applicable Non-Competition Period following his termination and (ii) to the extent the Executive elects to continue
health coverage under COBRA, reimburse him for the premiums he pays to extend such coverage for the applicable Non-Competition Period
following his termination; provided, however, that the reimbursement will cease if he obtains other employment that offers group health
benefits. In addition, the Company’s Board of Directors, in its sole discretion, may elect to vest part or all of any outstanding
stock options or equity awards; and |
| (b) | With respect to a Qualifying Termination that occurs within twelve (12) months following a Change of Control
Event and provided the Executive executes and does not revoke the Release, the Company will (i) pay the Executive in a lump sum an
amount equal to two (2) times his Base Salary and Target Bonus, (ii) fully vest all of his outstanding stock options and equity
awards and (iii) to the extent the Executive elects to continue health coverage under COBRA, reimburse him for the premiums he pays
to extend such coverage for up to eighteen (18) months following his termination; provided, however, that such reimbursement shall cease
if he obtains other employment that offers group health benefits. |
Clawbacks. The
Executive’s compensation is subject to recovery under any law, government regulation or stock exchange listing requirement (or any
Company policy adopted pursuant thereto).
“Good Cause” generally
includes (subject to certain cure provisions):
(i) the
Executive willfully engaged in acts or omissions determined to constitute fraud, breach of fiduciary duty or intentional wrongdoing;
(ii) the
Executive is convicted of, or enters a plea of guilty or nolo contendere to charges of,
any criminal violation involving fraud, theft or dishonesty;
(iii) the
Executive is convicted of, or enters a plea of guilty or nolo contendere to charges of,
any non-vehicular felony which has or is substantially likely to have a material adverse effect on the Executive’s ability to carry
out his duties under the Employment Agreement or on the reputation or activities of the Company;
(iv) the
Executive habitually abuses alcohol, illegal drugs or controlled substances or non-prescribed prescription medicine, and such abuse materially
and adversely interferes with the performance of the Executive’s duties and responsibilities to the Company;
(v) the
Executive materially breaches the terms of any agreement between the Executive and the Company relating to the Executive’s employment;
(vi) the
Executive engages in acts or omissions constituting gross negligence by Executive in the performance (or non-performance) of his duties;
or
(vii) the
Executive fails to comply with any material directive of the CEO of the Company consistent with the position of CRO.
“Good Reason”
generally means (subject to certain cure provisions):
(i) the
material diminution of any duties, responsibilities and authorities inconsistent in any respect with the Executive’s position as
a CRO;
(ii) any
failure by the Company to comply with any of the compensation provisions of the Employment Agreement (except for an isolated, insubstantial,
inadvertent or non-material failure not occurring in bad faith and which is promptly remedied by the Company); or
(iii) the
Company materially breaches the terms of any agreement between the Executive and the Company relating to the Executive’s employment,
or materially fails to satisfy the conditions and requirements of the Employment Agreement.
A “Change
in Control Event” means:
(i) any
transaction in which shares of voting securities of the Company representing more than 50% of the total combined voting power of all outstanding
voting securities of the Company are issued by the Company, or sold or transferred by the stockholders of the Company;
(ii) the
merger or consolidation of the Company with or into another entity resulting in those persons and entities who beneficially owned voting
securities of the Company representing more than 50% of the total combined voting power of all outstanding voting securities of the Company
immediately prior to such transaction ceasing to beneficially own voting securities of the Company representing more than 50% of the total
combined voting power of all outstanding voting securities of the surviving corporation or resulting entity immediately after such merger
or consolidation; or
(iii) the
sale of all or substantially all of the Company’s assets unless those persons or entities who beneficially owned voting securities
of the Company representing more than 50% of the total combined voting power of all outstanding voting securities of the Company immediately
prior to such asset sale continue to beneficially own voting securities of the purchasing entity representing more than 50% of the total
combined voting power after the sale.
Immediately prior to joining
the Company, Mr. Elliffe was Head of Investment Risk at Selective Insurance, Branchville, NJ, a property and casualty insurance company.
From 2015 through part of 2020, he was Head of Asset Liability Management & Hedging at Transamerica Corporation, Baltimore, MD,
a diversified financial services corporation providing services in insurance, sales financing, consumer and commercial loans, equipment
leasing, mortgage banking, computer services and mutual funds. From 2009 into 2015, Mr. Elliffe was Head of the Equity Risk Management
Department, after serving as Head of Strategy and Analytics, at Lincoln Financial Group, Philadelphia, PA, a holding company operating
multiple insurance and investment management businesses through subsidiary companies. Prior to this, he held various roles related to
portfolio management and analytics at the Man Group, PLC, Toronto, Canada, and RBC Insurance, Dublin, Ireland and Toronto, Canada.
Mr. Elliffe earned a BSc in Physics from Dublin City University in Ireland, a Ph.D. in Astrophysics from the University of Glasgow
in the United Kingdom and an MBA (Major in Finance and Management) from the University of Pennsylvania Wharton School.